NCT05220735

Omega-3 Fatty Acid Supplementation and Fractional Iron Absorption in Obese South African Women

Completed NA Last updated 22 November 2023

What this trial tests

NA trial testing Omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFA) in Obesity in 33 participants. Completed in 30 September 2023.

Timeline

7 March 2022

Primary endpoint
10 March 2023

30 September 2023

Quick facts

Lead sponsor	Swiss Federal Institute of Technology
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	33
Start date	7 March 2022
Primary completion	10 March 2023
Estimated completion	30 September 2023
Sites	1 location across South Africa

Drugs / interventions tested

• Omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFA)

Conditions studied

• Obesity — all drugs for Obesity →

Sponsor

Swiss Federal Institute of Technology

Who can join

Adults 18 to 35, female only, with Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In South Africa the prevalence of obesity in women of reproductive age is high; these women also have a high risk for iron deficiency (ID). Obesity is associated with low-grade systemic inflammation, which was shown to increase the expression of hepcidin, leading to a reduction in duodenal iron absorption. Thus, alleviating the sub-clinical inflammation associated with obesity could improve iron absorption and status. Supplementation with n-3 long-chain polyunsaturated fatty acids (LCPUFA) has been shown to reduce inflammation in obese individuals. A stable iron isotope study will be performed to investigate the effect of n-3 LCPUFA supplementation on fractional iron absorption in obese South African women.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Omega-3 Long-Chain Polyunsaturated Fatty Acid Supplementation Did Not Reduce Inflammation to Improve Iron Absorption in South African Women Living with Overweight or Obesity.
   Uyoga MA, Baumgartner J, Malan L, Lewies A, et al · · 2026 · PMID 41456679 · DOI 10.1016/j.tjnut.2025.101280